PharmIdea
PharmIdea is a Latvia-headquartered, EU GMP-certified CDMO and proprietary generics manufacturer specializing in sterile injectable drugs in vials, serving pharmaceutical companies across 60+ countries with contract manufacturing, licensing, and nine in-house generic products.
- Company typePrivate
- Founded2010
- HeadquartersOlaine, Latvia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmIdea does
PharmIdea (legal entity SIA PHARMIDEA) is a Latvia-headquartered, privately held pharmaceutical manufacturer and CDMO/CMO that is the only producer of sterile drugs in vials in Latvia. Founded in 2005 with EU GMP certification achieved in 2010, the company has accumulated 15+ years of sterile drug technology development, registration documentation, and manufacturing experience, with regulatory approvals from the European Union plus 14+ additional countries including Saudi Arabia, UAE, South Korea, Canada, Russia, Thailand, Philippines, Malaysia, Kuwait, and Jordan. Its products are registered and distributed in 60+ countries across Europe, Africa, Asia, and the Americas.
The technology stack centers on three sterile manufacturing platforms — lyophilization (freeze-drying), aseptic filling for 2-30 ml vials, and terminal steam sterilization (autoclaving) — supplemented by in-house analytical capabilities (HPLC, UV/VIS spectrophotometry, SCF extraction), full serialization (GTIN/NTIN/PPN data matrix, aggregation), and ICH- and EU-pharmacopoeia-compliant quality control. Annual production capacity reaches up to 1 million sterile vials. The proprietary generic portfolio spans nine SKUs across oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases (Zoledronic Acid). Active R&D pipeline includes Semaglutide finished dosage form, Caspofungin lyophilized form improvement, Isavuconazole capsules, and a Sugammadex sterile injection technology program.
Revenue is generated through four streams: contract manufacturing (batch production for pharma clients), contract development (validation batches, stability studies, registration documentation), product licensing (transfer of EMA/ICH-compliant dossiers to client markets), and direct sales of proprietary generics. The GTM is enterprise field sales to pharmaceutical companies, supported by active participation in international events (CPhI, ACHEMA, euroPLX, WHX Dubai, BIOPLUS-INTERPHEX) and a channel partner network spanning Europe, Middle East, Africa, and Southeast Asia. R&D partnerships include the Latvian Organic Synthesis Institute, the FBMTKC competence center, SIA Cellboxlab (COMPETE/Ozempic project), ProJect Pharmaceutics, and the LAĶIFA industry association. The company employs 100+ professionals led by CEO and board member Vitālijs Skrīvelis.
PharmIdea firmographics
Firmographics- Name
- PharmIdea
- Legal name
- SIA PHARMIDEA
- Website
- https://pharmidea.lv
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmIdea is a Latvia-headquartered, EU GMP-certified CDMO and proprietary generics manufacturer specializing in sterile injectable drugs in vials, serving pharmaceutical companies across 60+ countries with contract manufacturing, licensing, and nine in-house generic products.
- Ownership category
- akta.pro rank
PharmIdea industry classification
Industry- Product category
- Contract Sterile Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where PharmIdea is headquartered
LocationHeadquarters
- HQ city
- Olaine
- HQ country
- Latvia
- HQ region
- Europe
Offices1 record
Markets served
PharmIdea business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract manufacturing services (CMO/CDMO): PharmIdea manufactures generic sterile medications in vials for pharmaceutical companies on a contract basis. Services include technology development, validation batch production, stability studies, and documentation preparation for drug registration.
- Product licensing: Licensing of finished pharmaceutical products with ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, enabling clients to register products in their markets.
- Investigational drug development and manufacturing: Development services for investigational medicinal products (IMP) including formulation optimization, technology development, and manufacturing for Phase I-III clinical trials, including batch packaging and labeling.
- Finished pharmaceutical product sales: Direct sales of proprietary generic sterile medications in therapeutic areas including oncology, obstetrics, antifungal, cardiology, and anesthesia.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Monthly | Visual Control and Packaging Operator position |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
PharmIdea product offering
Product offeringCore offering
PharmIdea is a Latvia-based pharmaceutical company that develops and manufactures sterile generic drugs in vials, offering a portfolio of nine injectable products across oncology, obstetrics, antifungal, cardiology, and anesthesia therapeutic areas. The company also provides contract development, contract manufacturing, and product licensing services for pharmaceutical clients globally, with production capacity up to 1 million sterile vials annually using lyophilization, aseptic filling, and autoclaving technologies. All operations are conducted under EU GMP certification with regulatory approvals from 14+ countries.
Product overview
PharmIdea is a Latvia-based pharmaceutical company specializing in the development and manufacturing of sterile generic drugs in vials. The company offers a portfolio of 9 generic pharmaceutical products spanning therapeutic areas including oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal treatments (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases management (Zoledronic Acid). Alongside its product portfolio, PharmIdea provides comprehensive contract services including contract manufacturing (utilizing lyophilization, aseptic filling, and autoclaving technologies with capacity up to 1 million sterile vials annually), contract development, product licensing with EMA/ICH compliant documentation, serialization, and investigational medicinal product development for clinical trials. The company is the only sterile drug manufacturer in Latvia and operates as a CDMO/CMO serving international markets across 60+ countries.
Differentiator
Problem solved
Functional benefit
Products and services
- Bortezomib Antineoplastic agent (powder for solution for injection at 3.5 mg) for the treatment of multiple myeloma and mantle cell lymphoma.
- Atosiban Tocolytic agent (solution for injection 6.75 mg/0.9 ml and concentrate for solution for infusion 37.5 mg/5 ml) indicated to delay imminent pre-term birth.
- Carbetocin Oxytocin analog (solution for injection at 100 mcg/ml) for the prevention of postpartum haemorrhage due to uterine atony after Caesarean section under epidural or spinal anaesthesia.
- Anidulafungin Systemic antifungal agent (powder for concentrate for solution for infusion at 100 mg) for the treatment of invasive candidiasis in adults.
- Micafungin Echinocandin antifungal (powder for concentrate for solution for infusion at 50 mg) for the treatment of invasive candidiasis in adults and children.
- Levosimendan Calcium sensitizer (concentrate for solution for infusion at 2.5 mg/ml) for the treatment of acutely decompensated severe chronic heart failure.
- Dexmedetomidine Sedative agent (concentrate for solution for infusion at 100 µg/ml in 200 µg/2 ml, 400 µg/4 ml, and 1000 µg/10 ml presentations) for sedation of intubated patients in intensive care units and sedation of non-intubated patients before diagnostic or surgical procedures.
- Sugammadex Selective relaxant binding agent (solution for injection at 100 mg/ml available in 200 mg/2 ml and 500 mg/5 ml presentations) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
- Zoledronic Acid Bisphosphonate (concentrate for solution for infusion at 4 mg/5 ml) for the treatment of hypercalcemia of malignancy and prevention of skeletal-related events in patients with progressive bone metastases.
- Contract Manufacturing Services Production of generic drugs in sterile vials using lyophilization (freeze-drying), aseptic filling, and autoclaving (terminal steam sterilization) technologies. Production capacity reaches up to 1 million sterile vials per year.
- Contract Development Services Full product lifecycle services including qualification of active substance, technology development, production of validation batches, stability studies, and preparation of documentation for drug registration in European and other global markets.
- Product Licensing Ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, with support for documentation adaptation according to client country requirements for product licensing.
- Serialization Services Serialization number generation and data matrix code assignment in GTIN/NTIN/PPN formats, with printing on cardboard packaging and aggregation of packaging, transport boxes, and pallets.
- Investigational Medicinal Products (IMP) Development Optimization of investigational medicinal product formulations, technology development in laboratory and commercial manufacturing conditions, and preparation of technical documentation for Phase I-III clinical trials, including batch packaging and labeling.
- Technology Transfer Transfer of production technology and analytical methods to/from third-party manufacturers in accordance with ICH and EU pharmacopoeia requirements.
Quantifiable outcome
- Production capacity up to 1 million sterile vials per year
- +2 more outcomes
Companies that use PharmIdea
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles3 records
PharmIdea technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
PharmIdea partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Latvijas Organiskās sintēzes institūts (Latvian Organic Synthesis Institute)coreResearch and development partnership with Latvia's leading organic synthesis institute for pharmaceutical development collaboration.
- Selectchemie AGminorDistribution partner for pharmaceutical products in certain markets.
- Logenex Pharm GmbHminorPharmaceutical distribution partner.
- Viet PhapminorDistribution partner in Vietnam market.
- Austell Laboratories LtdminorPharmaceutical distribution partner.
- Kuwait Saudi Pharmaceutical Industries Co.minorDistribution partner in Middle East markets.
- AV Medical CZ s.r.o.minorMedical products distribution partner.
- Polfa SA TarchominminorPharmaceutical manufacturing partnership.
- LIDDS ABminorPharmaceutical technology partnership.
- CellboxlabcoreResearch collaboration partner for COMPETE project on Ozempic generic drug quality assessment using in vitro test systems (Organs-on-Chips vs traditional test systems). Project funded by ERDF.
- SIA Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centrs (FBMTKC)coreCompetence center partnership for multiple research projects including Sugamadex sterile injection technology development, Caspofungin lyophilized form stability improvement, Isavuconazole capsule formulation, and Semaglutide finished dosage form technology development. Multiple projects funded by Recovery Fund.
- Latvijas Ķīmijas un farmācijas ismene asociācija (LAĶIFA)corePartnership in Latvian chemistry and pharmacy industry association network project for life sciences sector development, internationalization, and export promotion. Part of Recovery Fund project 5.1.1.2.i.0/3/24/A/CFLA/003.
- Samsung BiologicsminorMeeting with Samsung Biologics biotechnology division to discuss potential collaboration opportunities. Samsung Biologics is one of the world's largest contract manufacturing companies in the biopharmaceutical industry.
- Celltrion HealthcareminorMeeting with Celltrion Healthcare to discuss potential biosimilar product collaboration opportunities. Celltrion specializes in global marketing, distribution and sales of biological products including biosimilars.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
PharmIdea competitors and assessment
Company assessmentDirect peers
- Aenova: Aenova is a European CDMO offering sterile liquid and lyophilized manufacturing for generics and branded pharma, comparable in services, customer profile, and geographic scope.
- Recipharm: Recipharm is a European CDMO with significant sterile injectable fill-finish capacity serving global pharma, directly comparable to PharmIdea's CDMO model and customer base in sterile generics manufacturing.
- Almac Group: Almac offers sterile commercial manufacturing and contract development services for global pharma, including lyophilization, with comparable regulatory documentation and licensing services.
- Hovione: Hovione provides CDMO services including sterile injectable manufacturing and particle engineering for global pharma, overlapping with PharmIdea's aseptic fill-finish and lyophilization offerings.
- Vetter Pharma: Vetter specializes in aseptic filling of sterile injectables including lyophilization, directly mirroring PharmIdea's core technological offering for global pharma clients.
- Fareva: Fareva is a French-headquartered CDMO with sterile injectable manufacturing capabilities serving European and international pharma, directly comparable to PharmIdea's model.
- Siegfried Holding: Siegfried is a Swiss CDMO with sterile manufacturing of APIs and finished dosage forms, including injectables — comparable to PharmIdea's offering across the full pharma value chain.
Broad incumbents
- Catalent: Catalent is a large global CDMO with extensive sterile injectable capabilities; comparable to PharmIdea in service offering but operates at vastly greater scale and breadth.
Regional players
- Olainfarm: Olainfarm is a Latvian pharmaceutical manufacturer; same domestic market and overlapping therapeutic/generic portfolio, providing a regional benchmark for PharmIdea's domestic positioning.
- Grindeks: Grindeks is the largest Latvian pharmaceutical manufacturer with export reach, comparable as a same-country peer operating in generic injectable and finished dosage forms.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
PharmIdea social profiles
Digital presencePharmIdea financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmIdea leadership team
Management profileNumber of profiles
Profiles11 records
PharmIdea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmIdea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmIdea
What does PharmIdea do?
PharmIdea is a Latvia-based pharmaceutical company that develops and manufactures sterile generic drugs in vials, offering a portfolio of nine injectable products across oncology, obstetrics, antifungal, cardiology, and anesthesia therapeutic areas. The company also provides contract development, contract manufacturing, and product licensing services for pharmaceutical clients globally, with production capacity up to 1 million sterile vials annually using lyophilization, aseptic filling, and autoclaving technologies. All operations are conducted under EU GMP certification with regulatory approvals from 14+ countries.
Is PharmIdea a public or private company?
PharmIdea is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PharmIdea founded?
PharmIdea was founded in 2010. It employs 11 to 50 people.
Where is PharmIdea based?
PharmIdea is headquartered in Olaine, Latvia, in the Europe region.
How does PharmIdea make money?
Four revenue lines are on record. Contract manufacturing services (CMO/CDMO) is the primary driver. The others are product licensing, investigational drug development and manufacturing and finished pharmaceutical product sales.
Who are PharmIdea's main competitors?
Direct peers on record are Aenova, Recipharm, Almac Group, Hovione, Vetter Pharma, Fareva and Siegfried Holding. Catalent is listed as a broad incumbent. Regional players are Olainfarm and Grindeks.
Does PharmIdea have an API?
No public API is recorded for PharmIdea.
What industry is PharmIdea in?
PharmIdea's product category is Contract Sterile Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.